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Abstract
Introduction The co-existence of malaria with bacterial
infections is common in the tropics, hence the concurrent
use of antimalarials and antibiotics.
Objective This study aimed to investigate the effect on
pharmacokinetics and antimicrobial activity of co-admin-
istration of quinine and combined ampicillin–cloxacillin.
Methods In total, 14 healthy adults received single oral
doses of ampicillin–cloxacillin combination alone and with
quinine in a randomized crossover manner. Urine samples
collected at predetermined intervals over 48 h were anal-
ysed. The effect of quinine on minimum inhibitory con-
centrations (MICs) of ampicillin and cloxacillin were
determined against Staphylococcus aureus by agar diffu-
sion, agar dilution, and broth dilution.
Results Quinine significantly reduced the rate and extent
of excretion of ampicillin and cloxacillin (p\ 0.0002).
The total amounts of ampicillin and cloxacillin excreted
unchanged (Du?) alone were 217.10 ± 53.82 and
199.0 ± 64.29 mg versus 126.40 ± 50.63 and 135.20 ±
52.24 mg, respectively, with quinine. Respective maxi-
mum excretion rates (dDu/dtmax) for ampicillin and clox-
acillin were 43.55 ± 19.41 and 77.64 ± 29.65 mg/h alone
versus 18.01 ± 8.52 and 53.16 ± 20.72 mg/h with qui-
nine. This indicates a significant reduction in Du?and dDu/
dtmax by 41.78 and 58.65 % for ampicillin and 32.06 and
31.53 % for cloxacillin. Conversely, the disposition of
quinine was unaffected by ampicillin–cloxacillin (p[ 0.1).
The MIC of antibiotics alone versus with quinine, respec-
tively, were 0.11 ± 0.04 and 0.78 ± 0.1 lg/ml for ampi-
cillin, and 0.18 ± 0.1 and 0.92 ± 0.4 lg/ml for
cloxacillin, with a five- to sevenfold increase (p[ 0.01);
indicating a decrease in antimicrobial activity by quinine.
Conclusions Quinine therefore, reduced the bioavail-
ability and the antimicrobial activity of ampicillin–clox-
acillin upon co-administration, which may have therapeutic
implications. Caution is required with the co-administra-
tion of these medicines.
Key Points
This paper describes how quinine, a quinolone
antimalarial, affects the pharmacokinetics and
antibacterial properties of combined ampicillin–
cloxacillin.
Quinine markedly reduced the bioavailability of
ampicillin–cloxacillin combination in healthy
subjects.
Quinine also reduced the sensitivity of cloxacillin–
ampicillin to Staphylococcus aureus by increasing
the minimum inhibitory concentration by over
sixfold.
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1 Introduction
The co-administration of different drugs is imperative to
achieve a desired therapeutic objective or treat coexisting
diseases [1]. For example, the concurrent use of antibac-
terials and antimalarials is common in the tropics because
malaria is frequently associated with other infections such
as those of the respiratory tract, urinary tract, or ear, sex-
ually transmitted infections (STIs), and diarrhea, among
other infections [2]. Although numerous benefits can be
derived from co-administration of different drugs, the
expected therapeutic outcome is sometimes affected by
drug–drug interactions [3], which have been demonstrated
scientifically in the literature.
For instance, earlier studies carried out in healthy adults
revealed the presence of pharmacokinetic interactions
between quinoline antimalarials and antibiotics when co-
administered [4–7]. These interactions markedly reduced
bioavailability and could result in sub-therapeutic drug
levels as well as treatment failure, with implications for
therapeutic outcomes and the safety and efficacy of the
antibiotics [8]. Worthy of note were scientific investiga-
tions that proved significant reduction in bioavailability of
some penicillins (ampicillin and cloxacillin) following oral
co-administration with quinoline antimalarials [4–7].
Nigeria is the largest country in Africa and the sixth
largest in the world, with a current growing population of
over 170 million people [9]. However, the country is pla-
gued with diverse infectious diseases, including malaria
and notable bacterial infections [10].
Patients, physicians, pharmacists, and other healthcare
providers may be unaware of the possible interactions
between antibiotics and antimalarials as well as the
mechanisms involved. It is therefore common practice to
co-administer antimalarial and antibiotic drugs.
Quinine, a quinoline antimalarial, has been in use for
over 400 years [11] and continues to play a significant role
in the management of malaria as one of the most important
drugs for the treatment of complicated, cerebral, and
resistant malaria [12, 13]. Ampicillin and cloxacillin are
among the most widely used penicillin derivatives [14],
with a wide spectrum of antibiotic activity when used in
combination or individually [15].
Penicillin antibiotics, including combined ampicillin–
cloxacillin (Ampiclox), amoxicillin and quinoline anti-
malarials such as quinine, artemisinin derivatives and
proguanil (a prophylactic), and occasionally chloroquine,
are readily available in the tropics for the management of
bacterial infections and malaria. Additionally, self-medi-
cation is common among this vast population, where the
average ratio of physicians to patients is extremely low
[16]. Consequently, the consumption of oral formulations
of antibiotics and antimalarials rank highest in the volume
of medications frequently administered; this is a potential
public health issue. A survey carried out in University
College Hospital (UCH), Ibadan, Nigeria, revealed that the
most prescribed medicines were antimalarials and more
than 50 % of these were prescribed concurrently with
antibacterial drugs [17].
Quinoline antimalarials have been found to reduce the
bioavailability of penicillin antibiotics by 40–70 %, with a
corresponding increase in minimum inhibitory concentra-
tion (MIC) and minimum bactericidal concentration
(MBC) by two- to seven fold [4–7, 18]. The extent of
interactions reported with the co-administration of these
often used drugs is expected to increase as a potential
public health issue; however, little has been done to create
awareness or investigate the extent of interactions or their
impact, especially on the therapeutic outcomes of penicillin
antibiotics.
Given the potentially wide impact antimalarial–antibi-
otic drug interactions could exert on patient care, this study
investigated the effect of co-administration of quinine and
ampicillin–cloxacillin on their respective pharmacokinetic
parameters in healthy Nigerian adult volunteers as well as
the effect of concomitant use on the antimicrobial activity
of ampicillin and cloxacillin.
2 Methods
2.1 Chemicals and Reagents
Quinine sulphate and secondary reference primaquine
diphosphate were obtained from BDH Chemicals (Poole,
UK). Cloxacillin sodium, amoxicillin trihydrate, and
ampicillin trihydrate secondary reference samples were
obtained from Fidson Pharmaceutical Ltd, Sango Ota,
Ogun State, Nigeria.
HPLC-grade acetonitrile and methanol were supplied by
Sigma Aldrich (BDH Chemicals). Analytical grade per-
chloric acid, diethyl ether, and sodium hydroxide pellets
were procured from BDH Chemicals.
Ampiclox capsules manufactured by Beecham Phar-
maceuticals, Brentford, UK (batch no. 100434 and NAF-
DAC [the Nigerian National Agency for Food and Drug
Administration and Control] no. 04-2401) and quinine
sulphate tablets manufactured by NEM Laboratories
(P) Ltd, Mumbai, India (batch no. 09-1 and NAFDAC no.
A4-1880) were purchased from a reputable pharmacy at
Ibadan. Other reagents and chemicals were of analytical
grade. Wire loop, cork borer, spatula, MaCarteny universal
bottles, transparent ruler, swab stick, cotton wool, alu-
minum foil, needle and syringes, slide, plastacin, cover
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slip, micropipette, and thermometer were supplied by and
used at the Medical Microbiology Department, UCH,
Ibadan, Nigeria.
2.2 In Vivo Analysis
2.2.1 Subjects
We recruited 14 healthy volunteers (ten males and four
females) aged 18–42 years (mean ± standard deviation
[SD] 26.71 ± 6.90) and weighing 49–77 kg (mean [SD]
64.92 ± 8.87) for the study; all provided written informed
consent. The study protocol was approved by the Joint
Ethics Committee of University of Ibadan/UCH, Ibadan,
Nigeria. All subjects were non-smokers; medical exami-
nation confirmed they had experienced no recent illness.
None of the subjects consumed any medication or alcohol
1 week prior to and throughout the period of the study.
2.2.2 Drug Administration and Sample Collection
Each subject observed an overnight fast and remained in
the fasting state for 4 h after drug administration. A stan-
dard meal was served thereafter and water was taken ad
labium. In a random cross-over design, volunteers were
distributed into three groups comprising four to five sub-
jects each and monitored for drug–drug interactions. For
the first study period, each volunteer in group 1 received a
single oral dose of quinine sulphate tablets (500 mg),
volunteers in group 2 each received a single oral dose of
ampicillin–cloxacillin combination capsule (Ampiclox;
1000 mg), and group 3 received both quinine sulphate
tablets (500 mg) and ampicillin–cloxacillin combination
capsule (1000 mg). A washout period of 1 week was
observed, and at the end of the third study period, all 14
subjects had received the antimalarial drug (quinine sul-
phate tablets) alone, the antibiotic drugs (ampicillin–clox-
acillin combination capsule) alone, and a combination of
both antimalarial and antibiotic drugs
After drug administration for each arm, total urine voi-
ded was collected at 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24, and
48 h. The pH was determined and aliquots of 20 ml were
stored at –20 C until analysis.
2.2.3 Drug Analysis
An Adept series Cecil CE 4200, dual piston pump (Cecil
CE 4100), power stream, chromatography system manager
CE 4900 fitted with a ultraviolet (UV) detector and
LiChrospher 100 RP-18 (5 lm) Column with LiChro-
CART 125 9 4.0 mm I.D were used for sample analysis.
Two reverse-phase high-performance liquid chromatogra-
phy (HPLC) methods were used to determine drug
concentrations in urine samples. Cloxacillin and quinine
were analyzed using a modified and validated HPLC
method described by Babalola et al. [5] for quinine, while
ampicillin was analyzed using a developed and validated
method. Amoxicillin was used as the internal standard (IS)
for the determination of ampicillin, while primaquine was
the IS used for determining cloxacillin and quinine in urine
samples.
For the determination of ampicillin, 40 ll (equivalent to
20 lg/ml) of amoxicillin (IS) was added to 50 ll urine in a
2-ml Eppendorf tube, and the final volume was made up to
1 ml, with the mobile phase consisting of acetonitrile and
0.02 M potassium phosphate buffer, pH 4.5 (15:85 % v/v).
The mixture was vortex mixed for 20 s then centrifuged at
2500 rpm for 5 min. The supernatant (20 ll) was injected
into a C-18 column and the mobile phase was pumped at a
flow rate of 0.6 ml/min.
For cloxacillin, 20 ll (equivalent to 10 lg/ml) of the
primaquine (IS) was added to 100 ll of urine in a 2.0-ml
Eppendorf tube, and the final volume was made up to 1 ml,
with the mobile phase consisting of methanol, acetonitrile,
and 0.02 M potassium phosphate buffer (10:25:65 % v/v/
v), at a pH of 4.2. The solution was mixed with the vortex
mixer for 20 s then centrifuged at 2500 rpm for 5 min. A
total of 20 ll of the supernatant was injected and the
mobile phase was pumped at a flow rate of 1.0 ml/min.
For quinine, 1 ml of urine was placed in a 10-ml tapered
extraction tube and 20 ll of 100 lg/ml IS (primaquine)
solution was added. 200 ll of perchloric acid was also
added and mixed for 5 s. 1 ml of 5 M NaOH and 4 ml of
ether were further added, followed by whirl mixing for
1 min and centrifugation at 3000 rpm for 10 min. The ether
layer was transferred into another tube and 100 ll of 0.1 M
HCl was added. After whirl mixing for 1 min and cen-
trifuging for 5 min, a 20-ll aliquot of the aqueous layer
was injected into the HPLC. The mobile phase
methanol:acetonitrile:buffer (0.02 M KH2PO4) in the ratio
(10:25:65 v/v/v) at pH 4.2 used for cloxacillin was also
used but with a flow rate of 0.5 ml/min.
Detection of the three drugs was achieved with a UV
detector at a wavelength of 225 nm.
Between-day and within-day co-efficient of variation
(CV %) were determined and found to vary between 1 and
9 %, while recovery ranged between 92 and 107 %. The
limit of detection (LOD) for ampicillin, cloxacillin, and
quinine were 2, 0.8, and 0.02 lg/ml, respectively.
2.3 In Vitro Analysis
Microorganisms were first identified using catalase and
coagulase tests for Staphylococcus aureus then indole and
motility tests for the strains of Escherichia coli. An
antimicrobial sensitivity test was carried out and
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Fig. 1 a Excretion rate, b Cumulative amount and c Amount remaining to be excreted of ampicillin in urine after a single oral dose of 500 mg of
the drug alone versus co-administration with 500 mg of quinine to 14 volunteers
(a) (b)



























































































Fig. 2 a Excretion rate, b Cumulative amount and c Amount remaining to be excreted of cloxacillin in urine after a single oral dose of 500 mg of
the drug alone versus co-administration with 500 mg of quinine to 11 volunteers
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Staphylococcus aureus was found out to be more suscep-
tible to the drugs investigated.
The MICs of the antibiotics were determined alone and
in combination with the antimalarial drug using three
methods: agar diffusion, agar dilution, and broth dilution.
The broth dilution method gave the best result. For the broth
dilution method, a liter of sterile nutrient broth was prepared
and 5 ml transferred into properly labeled test tubes (14 test
tubes for each drug and each combination, with three con-
trols). The tubes were corked with cotton wool and alu-
minum foil, then sterilized in an autoclave for 20 min. Upon
cooling, 250 mg of each drug was dissolved in 10 ml sterile
distilled water and diluted further to obtain 250 lg/ml. This
concentration was serially diluted further using a double
dilution method, thus reducing the concentrations to 125,
62.5, 31.25, 15.63, 7.81, 3.91, 1.98, 0.98, 0.49, 0.24, 0.12,
0.06, and 0.03 lg per 5 ml of each of the drugs. The solu-
tions in the test tubes were mixed thoroughly and inoculated
with about 0.1 ml of 1 in 70 dilution of an overnight broth
culture of test organism. The solutions in the test tubes were
incubated at 37 C for 48 h. The MIC was the lowest
concentration that prevented the growth of the controlled S.
aureus (ATCC 25923) after 24 h incubation, which was
indicated by clear broth solution.
2.4 Data Analysis
Pharmacokinetic parameters, including amounts of
unchanged drug excreted in urine (Du?), maximum peak
of excretion (Dumax), elimination half-life (t), and time
to maximum peak of excretion (tmax), were computed
using the non-compartmental pharmacokinetic
computation.
Peak area ratios were generated from chromatograms for
generating calibration curves, from which the concentra-
tions where determined by interpolating peak area ratios to
corresponding curves for each drug.
The following pharmacokinetic parameters were deter-
mined from urine data:
Excretion rate ¼ dDu
dt
where Du is the amount excreted in time interval and t is
the time midpoint.
% dose excreted unchanged in urine
¼ Total amount of drug excreted unchanged in urine 100
Total amount of drug administered
Du? = Total amount of drug excreted unchanged in
urine.
This is calculated by the sum of the amount of drug
excreted unchanged in urine at intervals.
Maximum excretion rate (dDu/dtmax) and time required
to reach maximum peak of excretion tmax were obtained
directly from the urine data for each volunteer.
The t was calculated using the formula
t1=2 ¼ 0:693=K;





























































Fig. 3 a Excretion rate, b Cumulative amount and c Amount remaining to be excreted of quinine in urine after a single oral dose of 500 mg of
the drug alone versus co-administration with 1000 mg of ampicillin-cloxacillin to 14 volunteers
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where K is the elimination rate constant, which was cal-
culated by the linear regression analysis of log excretion
rate-time profile.
Results were recorded as mean ± SD with 95 % con-
fidence intervals (CIs). Student’s t test (two-tailed, paired)
was performed on the pharmacokinetic parameters
obtained using GraphPad Software (GraphPad Prism Ver-
sion 3.0 for Windows) and Microsoft Excel 2007 soft-
ware. In all, a value of p\ 0.05 was considered
statistically significant.
3 Results
Details of the pharmacokinetic parameters obtained for
ampicillin, cloxacillin, and quinine before and after co-
administration in each subject are shown in Tables 1, 2, 3.
Figures 1–3 show urinary profile of the drugs (ampicillin,
cloxacillin and quinine) by excretion rate, cumulative and
amount remaining to be excreted (ARE) methods. Wide
inter- and intra-individual variations were observed in the
results obtained. Table 4 shows the pH of urine voided by
volunteers after drug administration. There was no signif-
icant effect on the pH values with drugs administered
Co-administration of quinine and ampicillin–cloxacillin
resulted in a significant decrease in the Dumax and mean
Du? of ampicillin (p\ 0.001) and cloxacillin (p\ 0.05).
However, the parameters of quinine were not significantly
affected (p[ 0.1).
The Du? and Dumax for ampicillin were decreased in all
subjects after co-administration with quinine. However, for
cloxacillin, Du? and dDu/dtmax decreased only in 11 of the
14 subjects after co-administration of ampicillin–clox-
acillin with quinine. Du? and dDu/dtmax for administration
of quinine alone were comparable with the corresponding
values when co-administered with ampicillin–cloxacillin in
all subjects, indicating a lack of significant decrease in
pharmacokinetics.
The dDu/dtmax of ampicillin and cloxacillin was
decreased by 58.65 and 31.53 %, whereas their Du? was
decreased by 41.78 and 32.06 %, respectively (p\ 0.05).
The tmax at maximum excretion and the t of ampicillin
and cloxacillin were in most cases longer after concurrent
intake with quinine; however, differences were not statis-
tically significant (p[ 0.05). The percentage decrease in
dDu/dtmax and Du
? of quinine when co-administered with
ampicillin–cloxacillin in the 14 volunteers was\2 % in all
subjects.
The results of the effect of quinine on the antimicrobial
activities of ampicillin and cloxacillin against S. aureus are
summarized in Table 5. The mean MIC of the drugs
investigated alone and in combination with quinine were
0.11 ± 0.04 and 0.78 ± 0.1 lg/ml for ampicillin, indicat-
ing a sevenfold increase in MIC, 0.18 ± 0.1 and
0.92 ± 0.4 lg/ml for cloxacillin with a fivefold increase in
MIC, and 0.02 ± 0.01 and 0.25 ± 0.1 lg/ml for ampi-
cillin–cloxacillin, with a 13-fold increase in MIC. There
was a significant decrease in the antimicrobial activity of
ampicillin, (p = 0.0001), cloxacillin (p = 0.0122), and
ampicillin–cloxacillin (p = 0.0145) when used concomi-
tantly with quinine.
4 Discussion
This is the first time in vitro and correlating in vivo
methodologies have been used to establish drug–drug
interactions between quinoline antimalarials and penicillin
antibiotics, confirming the stage of interaction to be the
absorption phase after oral co-administration of penicillin
antibiotics and quinoline antimalarials. The study also
compared the effect of quinine on ampicillin as well as
cloxacillin for the first time, unlike previous studies in
which only the effects of quinoline antimalarials on clox-
acillin [5–7] or ampicillin [4] have been evaluated. Addi-
tionally, this study is the first to investigate the effect of
penicillin antibiotics on quinoline antimalarials and vice
versa after co-administration.
In this study, in vivo drug–drug interactions were mon-
itored using data from urinary drug excretion, which is non-
invasive and useful for the determination of pharmacoki-
netic parameters when a drug or its metabolite is reasonably
excreted in urine [19, 20]. Ampicillin and cloxacillin fall
into the class of drugs excreted unchanged in reasonable
amounts in urine after oral administration. The use of uri-
nary data in this study is thus justified given that any drug
that appears in urine must have been first absorbed into the
blood. Although plasma data is the gold standard for
pharmacokinetic/pharmacodynamic measurements, urinary
excretion data were used in lieu of plasma data, especially
as the drugs in this study, specifically the antibiotics, are
largely excreted unchanged in urine, and urine collection is
a non-invasive method for such studies [20].
The decrease in total amount of ampicillin and clox-
acillin excreted unchanged in urine by 41.78 and 32.06 %,
respectively, as well as the marked reduction in Dumax by
58.65 and 31.53 %, indicate significant reductions in
ampicillin (p\ 0.0001) and cloxacillin (p\ 0.0190)
bioavailability following oral co-administration of ampi-
cillin–cloxacillin and quinine tablets. Quinine reduced the
rates and extent of absorption of ampicillin and cloxacillin.
The pattern of results obtained and the half-life values in
this study correlate with in vivo reports in earlier studies
[4–6].
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In 1985, Ali [4] reported a similar interaction between
ampicillin and chloroquine, whereby a significant reduc-
tion in percentage of ampicillin excreted in urine (34 %;
p\ 0.005) was observed. However, the effect of quinine
on rates and extents of excretion of ampicillin in this
study were more pronounced than that reported for
chloroquine.
The possible effect of chloroquine on the urinary
excretion of cloxacillin when co-administered with ampi-
cillin–cloxacillin was also investigated earlier in eight
healthy adult volunteers [6]. A significant reduction (64 %)
in the urinary excretion of cloxacillin was reported.
Additionally, the effect of oral co-administration of pro-
guanil with cloxacillin was also evaluated in seven healthy
adult volunteers. A 48 % decrease in both rate and extent
of absorption of cloxacillin was reported [6]. A recent
study reported a reduction in the mean amount of clox-
acillin excreted in urine following the co-administration of
artesunate with amoxicillin–cloxacillin [7]. Nine of the 14
subjects showed a significant decrease 39 % (p = 0.0006)
in the urinary excretion (Du?) of cloxacillin, whereas five
subjects (36 %) showed a significant increase of 27 %
(p = 0.014) when amoxicillin and artesunate were co-ad-
ministered. The result showed a significant reduction in the
bioavailability of cloxacillin after co-administration with
artesunate.
All except one [4] of these earlier studies were con-
ducted in our laboratory, and both in vivo and in vitro
results correlate with those observed in this study.
dDu/dtmax and Du
?, tmax, and t obtained for quinine in
urine after a single oral dose of 500 mg and when co-
administered with ampicillin–cloxacillin 1000 mg in 14
healthy volunteers showed no significant difference (p[
0.1), indicating that quinine was not affected by co-ad-
ministration with ampicillin–cloxacillin . The results of this
study thus suggest a significant drug–drug interaction
between quinine and ampicillin–cloxacillin in a manner
that primarily affects the bioavailability of the penicillin
antibiotics.
The significant decrease in total amount of antibiotics
(such as ampicillin and cloxacillin) excreted unchanged in
urine as well as the marked reduction in maximum peak of
excretion clearly indicate significant reductions in their
bioavailability following oral co-administration of these
penicillins with quinoline antimalarials, since only drugs
absorbed in the blood can be eliminated via the kidney. In
general, the quinoline antimalarials reduced the rates and
extent of absorption of the penicillin antibiotics.
Table 1 Urinary excretion data of ampicillin after a single oral dose of ampicillin–cloxacillin 1000 mg alone and with quinine 500 mg in 14
healthy volunteers
Volunteer Du? (mg) dDu/dtmax (mg) % dose excreted tmax (h) t (h)
Amp Amp ? Qn Amp Amp ? Qn Amp Amp ? Qn Amp Amp ? Qn Amp Amp ? Qn
A 226.54 180.29 59.24 26.61 45.31 36.06 1.50 1.50 0.54 1.36
B 252.38 167.36 70.13 26.48 50.48 33.47 1.50 1.50 1.50 0.98
C 281.22 125.26 53.62 19.36 56.24 25.05 1.50 1.50 0.36 1.78
D 265.75 89.46 72.00 10.35 53.15 17.89 0.75 1.50 1.42 2.48
E 199.97 96.23 37.95 17.24 39.99 19.25 1.50 1.50 0.69 1.87
F 217.89 118.47 19.94 24.12 43.58 23.69 3.00 1.50 2.17 1.98
G 270.11 136.17 46.83 16.20 54.02 27.23 1.50 0.75 1.50 1.16
H 183.75 90.83 21.22 8.61 36.75 18.17 3.00 1.50 2.48 2.77
I 258.61 247.44 52.20 37.62 51.72 49.49 0.75 1.50 1.05 1.15
J 270.47 162.26 30.34 18.29 54.09 32.45 3.00 1.50 2.36 1.98
K 100.77 48.08 17.18 4.67 20.15 9.62 0.75 1.50 2.31 4.95
L 146.57 75.22 31.08 13.53 29.31 15.04 3.00 1.50 1.73 2.10
M 172.96 124.62 68.65 13.82 34.59 24.92 1.50 1.50 1.46 2.17
N 192.58 107.87 29.29 15.19 38.52 21.57 1.50 3.00 1.17 2.77
Mean 217.10 126.40 43.55 18.01 43.42 25.28 1.77 1.55 1.48 2.11
SD 53.82 50.63 19.41 8.52 10.76 10.13 0.86 0.46 1.00 10.76
Significance 0.0001 (S) 0.0001 (S) 0.0001 (S) 0.4202 (NS) 0.0637 (NS)
% difference 41.78 58.65 41.78 12.43 29.86
AMP ampicillin, Dumax maximum peak of excretion, Du
? amount of unchanged drug excreted in urine, NS not significant, Qn quinine,
S significant, SD standard deviation, tmax time to maximum peak plasma concentration, t elimination half-life
p = 0.05 is taken as significant, p[ 0.05 is taken as not significant
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Although the mechanism of this interaction has not been
fully explained, the reduction of the bioavailability of these
antibiotics might be attributed to slower gastric emptying
and inhibition of gastric motility produced by antimalarials
[4]. Quinine has an anti-spasmodic effect [21, 22] and has
been shown to significantly attenuate extracellular potas-
sium transients in vitro [22]. Quinine thus initiates smooth
muscle contraction, especially in tubular organs of the
gastrointestinal tract, thereby preventing spasms of the
intestine. Such reduction in gastric motility may give rise
to acid hydrolysis of a b-lactam ring, with a lesser effect on
cloxacillin as a result of the presence of bulky side chains
that exhibit stearic hindrance around the b-lactam ring.
This, in addition to the chlorine atom on its phenyl ring,
makes it resistant to acid catalyzed hydrolysis in the
stomach or gastric breakdown [23] and hence may account
for the lesser effect of interaction on the bioavailability of
cloxacillin compared with ampicillin as observed in this
study.
Reduction of ampicillin and cloxacillin bioavailability
on oral co-administration with quinine could also be
attributed to adsorption of ampicillin and cloxacillin to
quinine in the gastrointestinal tract, formation of a complex
between the drugs that can result in reduction in bioavail-
ability of these antibiotics.
The in vitro results suggest that quinine significantly
(p\ 0.05) increased the MIC of ampicillin, cloxacillin,
and ampicillin–cloxacillin on S. aureus by sevenfold,
fivefold, and 13-fold, respectively. This strongly indicates a
significant in vitro interaction between the penicillin
antibiotics and quinoline antimalarial (quinine) tested. MIC
is used to establish the sensitivity and effectiveness of
antibiotics, and could also be a possible measure of
antimicrobial activity. The marked increase in MICs of
ampicillin, cloxacillin, and ampicillin–cloxacillin by sev-
enfold, fivefold, and 13-fold, respectively, when combined
with quinine and used against S. aureus is thus indicative of
a sharp decrease in sensitivity of the antibiotics tested. This
also suggests a significant decrease in antimicrobial activ-
ity of the antibiotics investigated, which may translate into
poor treatment outcome in clinical situations as well as
drug resistance in the long run. Although the mechanism by
which this happened is not clear, it could be attributed to
the formation of a complex between both drugs that pos-
sibly leads to reduced antimicrobial activity of the peni-
cillin antibiotics or an interaction that affects the beta-
Table 2 Urinary excretion data of cloxacillin after a single oral dose of ampicillin–cloxacillin 1000 mg alone and with quinine 500 mg in 14
healthy volunteers
Volunteer Du? (mg) dDu/dtmax (mg) % dose excreted tmax (h) t (h)
Clox Clox ? Qn Clox Clox ? Qn Clox Clox ? Qn Clox Clox ? Qn Clox Clox ? Qn
A 300.36 263.40 98.51 78.99 60.04 52.68 0.75 0.75 0.20 0.29
Ba 68.90 260.37 45.12 136.05 13.78 52.07 1.50 0.75 0.74 0.23
Ca 128.42 299.33 65.26 163.32 25.68 59.87 1.50 0.75 0.53 0.16
D 224.47 139.22 78.42 64.41 44.89 27.84 1.50 0.75 0.36 0.27
Ea 99.44 308.88 48.57 185.04 19.89 61.78 0.38 0.75 0.43 0.11
F 223.61 115.58 50.51 34.21 44.72 23.12 3.00 0.75 0.82 0.56
G 135.37 109.58 49.89 42.11 27.07 21.92 1.50 0.75 0.54 0.39
H 225.32 161.42 81.35 62.78 45.06 32.28 1.50 1.50 0.26 0.39
I 282.11 102.30 136.84 40.81 56.42 20.46 0.75 0.75 0.19 0.54
J 202.92 165.29 41.14 54.70 40.58 33.06 3.00 1.50 0.50 0.34
K 121.15 92.49 104.77 95.45 24.23 18.50 0.75 1.50 0.28 0.98
L 157.65 100.11 62.97 41.86 31.53 20.02 1.50 0.75 0.40 0.60
M 98.73 76.89 22.69 25.39 19.75 15.38 1.50 1.50 0.89 0.98
N 216.87 161.02 56.95 44.10 43.37 32.20 0.75 1.50 0.36 0.41
Mean 199.00 135.20 77.64 53.16 39.79 27.04 1.50 1.09 0.44 0.52
SD 64.29 52.24 29.65 20.72 12.85 10.45 0.82 0.39 0.24 0.25
Significance 0.0190 (S) 0.0363 (S) 0.0190 (S) 0.1516 (NS) 0.4138 (NS)
% difference 32.06 31.53 32.04 27.33 15.94
clox cloxacillin Dumax maximum peak of excretion, Du
? amount of unchanged drug excreted in urine, NS not significant, Qn quinine,
S significant, SD standard deviation, tmax time to maximum peak plasma concentration, t elimination half-life
p = 0.05 is taken as significant, p[ 0.05 is taken as not significant
a Not used to calculate the mean
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lactam ring. More studies are needed to confirm the
mechanism of interaction. Consequently, the effect of
quinoline antimalarials on penicillin antibiotics is central to
public health, especially where people self-medicate or
physicians prescribe antimalarials and antibiotics in areas
endemic for malaria and infections.
The results obtained in this study were comparable with
those reported in earlier studies [4–7, 24] and also showed
Table 3 Urinary excretion data of quinine after a single oral dose of quinine 500 mg alone and with ampicillin–cloxacillin 1000 mg in 14
volunteers
Volunteer Du (mg) dDu/dtmax (mg) % dose excreted tmax (h) t (h)
Qn Qn ? Amp–
clox
Qn Qn ? Amp–
clox
Qn Qn ? Amp–
clox
Qn Qn ? Amp–
clox
Qn Qn ? Amp–
clox
A 6.02 8.73 0.53 0.64 1.20 1.70 3.0 6.0 13.32 13.89
B 14.42 11.38 0.96 0.39 2.98 2.28 6.0 6.0 11.55 13.33
C 30.47 31.32 1.21 1.06 6.09 6.26 6.0 6.0 15.75 16.12
D 28.69 30.11 0.83 1.50 5.74 6.02 6.0 6.0 13.89 13.03
E 25.61 3.21 1.35 0.15 5.12 0.64 3.0 3.0 9.90 13.86
F 10.99 12.46 0.52 0.98 2.20 2.49 6.0 6.0 15.40 9.92
G 38.96 37.11 3.80 1.79 7.79 7.42 6.0 18.0a 13.58 11.45
H 29.00 16.89 3.60 0.66 5.80 3.38 6.0 18.0a 18.73 12.16
I 21.14 26.96 1.20 1.20 4.22 5.39 6.0 6.0 18.24 19.25
J 33.91 32.91 2.86 3.46 6.78 6.58 6.0 6.0 13.16 11.75
K 9.34 11.84 1.01 0.65 1.87 2.37 6.0 6.0 16.90 9.00
L 11.26 13.32 1.06 0.57 2.25 2.66 6.0 6.0 16.50 15.75
M 30.93 42.49 1.36 5.93 6.19 8.50 6.0 6.0 9.90 13.86
N 31.17 35.87 1.83 2.36 6.23 7.17 6.0 6.0 11.55 9.90
Mean 23.03 22.47 1.58 1.52 4.60 4.49 5.57 5.75 14.17 13.09
SD 10.60 12.62 1.07 1.54 2.12 2.53 1.09 0.87 2.86 2.75
Significance 0.9003 (NS) 0.9124 (NS) 0.8979 (NS) 0.6518 (NS) 0.3189 (NS)
% difference 24.32 3.80 2.39 3.13 7.62
Amp–clox ampicillin–cloxacillin, Dumax maximum peak of excretion, Du
? amount of unchanged drug excreted in urine, NS not significant, Qn
quinine, S significant, SD standard deviation, tmax time to maximum peak plasma concentration, t elimination half-life
p = 0.05 is taken as significant, p[ 0.05 is taken as not significant
a Not used to calculate the mean












A 6.62 ± 0.33 7.12 ± 0.25 7.42 ± 0.37
B 7.20 ± 0.33 7.24 ± 0.56 7.20 ± 0.38
C 7.12 ± 0.18 6.96 ± 0.44 7.05 ± 0.66
D 6.99 ± 0.43 6.45 ± 0.51 6.65 ± 0.24
E 6.47 ± 0.18 6.45 ± 0.14 6.56 ± 0.24
F 8.02 ± 0.33 7.70 ± 0.43 7.61 ± 0.40
G 7.54 ± 0.31 7.33 ± 0.20 7.34 ± 0.21
H 7.74 ± 0.35 7.37 ± 0.43 7.63 ± 0.39
I 6.87 ± 0.32 6.58 ± 0.30 6.69 ± 0.40
J 7.14 ± 0.15 7.13 ± 0.21 6.88 ± 0.23
K 7.64 ± 0.52 7.24 ± 0.29 7.54 ± 0.42
L 6.63 ± 0.69 6.44 ± 0.35 6.66 ± 0.32
M 6.99 ± 0.28 7.21 ± 0.27 7.13 ± 0.32
N 7.38 ± 0.10 7.19 ± 0.55 6.93 ± 0.26
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a clear correlation between in vivo and in vitro studies, thus
validating the significant reduction in bioavailability of
ampicillin and cloxacillin when co-administered with
quinoline antimalarials. However, it is imperative to note
that this interaction is at an absorption level based on a
proposed mechanism of action and in vitro interaction
studies; previous studies by our team have shown that the
dissolution of some antibiotics is reduced by quinoline
antimalarials [24].
The wide range of differences obtained from the CI in
this study is an indication of wide intra- and inter-indi-
vidual variability.
4.1 Limitations of the Study
Urinary elimination data were used in lieu of plasma data,
which is the gold standard. In this study, ampicillin and
cloxacillin were not analysed in plasma due to their
polarity and difficulties in carrying out solvent extraction
or precipitation methods, which led to low sensitivity.
Again, the already published plasma methods were not
reproducible after many attempts.
5 Conclusion
Quinoline antimalarials have repeatedly reduced the
in vivo and in vitro bioavailability as well as the antimi-
crobial activity of penicillins on co-administration in var-
ious studies. This is significant for oral administration of
the drugs and may be occurring at the absorption phase of
disposition.
The present study demonstrated significant drug-drug
interaction between ampicillin and cloxacillin versus qui-
nine (quinoline antimalarial) in a manner that correlates
with previous in vivo reports [5-7]. There seems to be an
in vitro–in vivo correlation in the interaction between
penicillins and some antimalarials, and dissolution is
probably the rate-limiting step in the absorption of
penicillins. Findings from this study are of utmost impor-
tance and caution is required in the co-administration of
these two classes of anti-infectives. It is also of public
health concern, as the interactions can contribute towards
observed antibiotic resistance and treatment failure being
experienced in recommended antibiotic treatment
regimens.
This interaction may also have clinical implications
judging from bacterial kill studies. The antagonism
demonstrated against antibiotics in these studies suggests
that penicillin antibiotics and quinoline antimalarials
should not be administered concurrently. Clinically, drugs
that interact should be avoided or given sufficiently far
apart that the interaction is minimized. In situations
involving two drugs of choice that may interact, dose
adjustment based on pharmacokinetic and therapeutic
considerations of one or both of the drugs may be neces-
sary. Drug administration can be separated by 2 h to avoid
interaction at the absorption level based on the disposition
of the penicillins, which have short half-lives.
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